On 2nd of October 2020...
“We’re going to have a meeting with the FDA in the next 30 days to discuss an accelerated approval, which is a conditional pathway, and we will agree to do another trial but after the product gets approved,” Mesoblast CEO Silviu Itescu told BioWorld.
So has the Type A Meeting request been submitted?
Also, a bit of loose reporting...
“The body of evidence around the use remestemcel-L in inflammatory conditions continues to build,” Itescu said. The stem cell therapy currently has emergency use authorization in the U.S. and Australia to treat ARDS due to COVID-19.
EUA has not been given!!!
We are still I'm a trial phase
On 2nd of October 2020... “We’re going to have a meeting with...
-
- There are more pages in this discussion • 4,242 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |